Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up Study on Resistance and Durability of Response to AbbVie Direct-Acting Antivirals in Chronic Hepatitis C
2012-003073-26Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of paritaprevir, glecaprevir, dasabuvir, ritonavir and ribavirin in chronic hepatitis C (CHC), sponsored by AbbVie Inc. Primary endpoint: Durability of treatment response. Started Jun 2013; status: completed.
02
Drugs
paritaprevirglecaprevirdasabuvirritonavirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2012-003073-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003073-26.